Effects of Composite Supplement Containing Astaxanthin and Sesamin on Cognitive Functions in People with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

In this study, the researchers evaluated the effects of a composite supplement containing food-derived antioxidants, specifically astaxanthin and sesamin (AS), on cognitive function in people with MCI.

Why It Was Studied

Dementia and its first or transitional stage, mild cognitive impairment (MCI), is a major concern for the aging Japanese society.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Twenty-one healthy participants with MCI were recruited in their double-blind placebo-controlled pilot study.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and pilot.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.

They were assigned to either an AS group, who received ingestible capsules containing AS, or a placebo group, who received identical placebo capsules.

What Was Measured

PubMed files the paper under topics including Cognitive Dysfunction, Dietary Supplements, Dioxoles, Lignans, Neuropsychological Tests, Pilot Projects and Xanthophylls.

The authors tagged it with the keywords Astaxanthin, CNSVS, cognitive functions, mild cognitive impairment, sesame extract and sesamin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Journal of Alzheimer's disease : JAD), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.